Articles of Association most recently amended 27 March 2012

April 04, 2012 07:59 ET | Source: ALK Abello ALK Abello

Articles of Association most recently amended 27 March 2012

Attachments

...

Recommended Reading

August 05, 2026 07:10 ET | Source: ALK Abello

Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy® 2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal...
Read More
June 15, 2026 03:00 ET | Source: ALK Abello

EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis

ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy® 1 mg, the first and only needle-free adrenaline treatment for...
Read More